Verdiva Bio halts mid-stage obesity trial of its GLP-1 pill, citing market evolution
read at Endpoints ↗Negative
Verdiva Bio, a well-funded private biotech, announced it has terminated one of its Phase 2 trials for its lead oral GLP-1 obesity candidate.
The company said the decision reflects a shift in the market landscape for obesity treatments, with evolving competitive dynamics influencing its strategy.
The move may delay Verdiva's entry into the lucrative obesity space and could weigh on investor sentiment as smaller firms face increasing pressure from established GLP-1 products.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Verdiva cans mid-stage obesity trial of GLP-1 pill, citing 'market evolution'”
read at Endpoints ↗86 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that